Bacteriocins From LAB and Other Alternative Approaches for the Control of Clostridium and Clostridiodes Related Gastrointestinal Colitis

The gut microbiome is considered as a promising target for future non-conventional therapeutic treatment of inflammatory and infectious diseases. The search for appropriate safe and beneficial (lactic acid bacterial and other) putative probiotic strains and/or their antimicrobial metabolites represe...

Full description

Bibliographic Details
Main Authors: Svetoslav D. Todorov, Hye-Ji Kang, Iskra V. Ivanova, Wilhelm H. Holzapfel
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-09-01
Series:Frontiers in Bioengineering and Biotechnology
Subjects:
Online Access:https://www.frontiersin.org/article/10.3389/fbioe.2020.581778/full
id doaj-db77cf7c512e43e1a3967b8b70759b47
record_format Article
spelling doaj-db77cf7c512e43e1a3967b8b70759b472020-11-25T01:55:10ZengFrontiers Media S.A.Frontiers in Bioengineering and Biotechnology2296-41852020-09-01810.3389/fbioe.2020.581778581778Bacteriocins From LAB and Other Alternative Approaches for the Control of Clostridium and Clostridiodes Related Gastrointestinal ColitisSvetoslav D. Todorov0Hye-Ji Kang1Hye-Ji Kang2Iskra V. Ivanova3Wilhelm H. Holzapfel4Wilhelm H. Holzapfel5Advanced Green Energy and Environment Institute (AGEE), Handong Global University, Pohang, South KoreaAdvanced Green Energy and Environment Institute (AGEE), Handong Global University, Pohang, South KoreaHEM Inc., Handong Global University, Pohang, South KoreaDepartment of General and Applied Microbiology, Faculty of Biology, Sofia University “St. Kliment Ohridski”, Sofia, BulgariaAdvanced Green Energy and Environment Institute (AGEE), Handong Global University, Pohang, South KoreaHEM Inc., Handong Global University, Pohang, South KoreaThe gut microbiome is considered as a promising target for future non-conventional therapeutic treatment of inflammatory and infectious diseases. The search for appropriate safe and beneficial (lactic acid bacterial and other) putative probiotic strains and/or their antimicrobial metabolites represents a challenging approach for combating several problematic and emerging infections. The process of selecting suitable strains, especially of lactic acid bacteria (LAB) with superior properties, has been accelerated and intensified during the past two decades, also thanks to recent developments in lab techniques. Currently, special focus is on the potential of antimicrobial metabolites produced by some LAB strains and their application as active therapeutic agents. The vision is to develop a scientific basis for ‘biotherapeutics’ as alternative to conventional approaches in both human and veterinary medicine. Consequently, innovative and promising applications of LAB to the therapeutic practice are presently emerging. An overview of the existing literature indicates that some antimicrobial metabolites such as bacteriocins, widely produced by different bacterial species including LAB, are promising biotherapeutic agents for controlling infections caused by potential pathogens, such as Clostridium and Clostridiodes. Non-conventional, safe and well designed therapeutic treatments may contribute to the improvement of gut dysbiotic conditions. Thereby gut homeostasis can be restored and inflammatory conditions such as gastrointestinal colitis ameliorated. Combining the knowledge on the production, characterization and application of bacteriocins from probiotic LAB, together with their antibacterial properties, appears to be a promising and novel approach in biotherapy. In this overview, different scenarios for the control of Clostridium spp. by application of bacteriocins as therapeutic agents, also in synergistic combination with antibiotics, will be discussed.https://www.frontiersin.org/article/10.3389/fbioe.2020.581778/fullClostridiumClostridiodesbacteriocinsprobioticsbiotherapeuticslactic acid bacteria
collection DOAJ
language English
format Article
sources DOAJ
author Svetoslav D. Todorov
Hye-Ji Kang
Hye-Ji Kang
Iskra V. Ivanova
Wilhelm H. Holzapfel
Wilhelm H. Holzapfel
spellingShingle Svetoslav D. Todorov
Hye-Ji Kang
Hye-Ji Kang
Iskra V. Ivanova
Wilhelm H. Holzapfel
Wilhelm H. Holzapfel
Bacteriocins From LAB and Other Alternative Approaches for the Control of Clostridium and Clostridiodes Related Gastrointestinal Colitis
Frontiers in Bioengineering and Biotechnology
Clostridium
Clostridiodes
bacteriocins
probiotics
biotherapeutics
lactic acid bacteria
author_facet Svetoslav D. Todorov
Hye-Ji Kang
Hye-Ji Kang
Iskra V. Ivanova
Wilhelm H. Holzapfel
Wilhelm H. Holzapfel
author_sort Svetoslav D. Todorov
title Bacteriocins From LAB and Other Alternative Approaches for the Control of Clostridium and Clostridiodes Related Gastrointestinal Colitis
title_short Bacteriocins From LAB and Other Alternative Approaches for the Control of Clostridium and Clostridiodes Related Gastrointestinal Colitis
title_full Bacteriocins From LAB and Other Alternative Approaches for the Control of Clostridium and Clostridiodes Related Gastrointestinal Colitis
title_fullStr Bacteriocins From LAB and Other Alternative Approaches for the Control of Clostridium and Clostridiodes Related Gastrointestinal Colitis
title_full_unstemmed Bacteriocins From LAB and Other Alternative Approaches for the Control of Clostridium and Clostridiodes Related Gastrointestinal Colitis
title_sort bacteriocins from lab and other alternative approaches for the control of clostridium and clostridiodes related gastrointestinal colitis
publisher Frontiers Media S.A.
series Frontiers in Bioengineering and Biotechnology
issn 2296-4185
publishDate 2020-09-01
description The gut microbiome is considered as a promising target for future non-conventional therapeutic treatment of inflammatory and infectious diseases. The search for appropriate safe and beneficial (lactic acid bacterial and other) putative probiotic strains and/or their antimicrobial metabolites represents a challenging approach for combating several problematic and emerging infections. The process of selecting suitable strains, especially of lactic acid bacteria (LAB) with superior properties, has been accelerated and intensified during the past two decades, also thanks to recent developments in lab techniques. Currently, special focus is on the potential of antimicrobial metabolites produced by some LAB strains and their application as active therapeutic agents. The vision is to develop a scientific basis for ‘biotherapeutics’ as alternative to conventional approaches in both human and veterinary medicine. Consequently, innovative and promising applications of LAB to the therapeutic practice are presently emerging. An overview of the existing literature indicates that some antimicrobial metabolites such as bacteriocins, widely produced by different bacterial species including LAB, are promising biotherapeutic agents for controlling infections caused by potential pathogens, such as Clostridium and Clostridiodes. Non-conventional, safe and well designed therapeutic treatments may contribute to the improvement of gut dysbiotic conditions. Thereby gut homeostasis can be restored and inflammatory conditions such as gastrointestinal colitis ameliorated. Combining the knowledge on the production, characterization and application of bacteriocins from probiotic LAB, together with their antibacterial properties, appears to be a promising and novel approach in biotherapy. In this overview, different scenarios for the control of Clostridium spp. by application of bacteriocins as therapeutic agents, also in synergistic combination with antibiotics, will be discussed.
topic Clostridium
Clostridiodes
bacteriocins
probiotics
biotherapeutics
lactic acid bacteria
url https://www.frontiersin.org/article/10.3389/fbioe.2020.581778/full
work_keys_str_mv AT svetoslavdtodorov bacteriocinsfromlabandotheralternativeapproachesforthecontrolofclostridiumandclostridiodesrelatedgastrointestinalcolitis
AT hyejikang bacteriocinsfromlabandotheralternativeapproachesforthecontrolofclostridiumandclostridiodesrelatedgastrointestinalcolitis
AT hyejikang bacteriocinsfromlabandotheralternativeapproachesforthecontrolofclostridiumandclostridiodesrelatedgastrointestinalcolitis
AT iskravivanova bacteriocinsfromlabandotheralternativeapproachesforthecontrolofclostridiumandclostridiodesrelatedgastrointestinalcolitis
AT wilhelmhholzapfel bacteriocinsfromlabandotheralternativeapproachesforthecontrolofclostridiumandclostridiodesrelatedgastrointestinalcolitis
AT wilhelmhholzapfel bacteriocinsfromlabandotheralternativeapproachesforthecontrolofclostridiumandclostridiodesrelatedgastrointestinalcolitis
_version_ 1724984664539529216